
A systematic review and meta-analysis confirm the efficacy of resmetirom, the first FDA-approved treatment for nonalcoholic steatohepatitis (NASH). Analyzing three clinical trials with 2,231 patients, the drug significantly improved fibrosis, liver fat content, and enzyme levels. Mild side effects like nausea and diarrhea were reported, reinforcing its potential as a groundbreaking NASH therapy.
Like
Save
Share